177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Titel:
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Auteur:
Strosberg, Jonathan R Caplin, Martyn E Kunz, Pamela L Ruszniewski, Philippe B Bodei, Lisa Hendifar, Andrew Mittra, Erik Wolin, Edward M Yao, James C Pavel, Marianne E Grande, Enrique Van Cutsem, Eric Seregni, Ettore Duarte, Hugo Gericke, Germo Bartalotta, Amy Mariani, Maurizio F Demange, Arnaud Mutevelic, Sakir Krenning, Eric P